NanoViricides Inc NNVC

Healthcare Biotechnology

NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

NYSEAM:NNVC - Post by User

NanoViricides Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Jun 11, 2024 10:45am

53 Views

Post# 36082683

Orally Administered NV-387 Results in Ideal Flat Blood Conce

JUST IN: $NNVC Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral EffectA First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT / ACCESSWIRE / June 11, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical-stage global leader in broad-spe...NNVC - Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario